Full text is available at the source.
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is characterized by late diagnosis and limited treatment options.
- PDAC is recognized as an aggressive form of cancer with high rates of recurrence.
- The tumor microenvironment in PDAC is often immunosuppressive, complicating treatment efforts.
- Personalized treatment strategies are being developed to target specific tumor-related antigens.
Simplified